

Functionalization of *N*-*tert*-butoxycarbonyl-7- and *N*-*tert*-butoxycarbonyl-8-bromo-10-azabicyclo[4.3.1]deca-3,7-dienes. A route to a ferruginine homolog*

N. Yu. Kuznetsov and Yu. N. Bubnov*


A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences,
28 ul. Vavilova, 119991 Moscow, Russian Federation.
Fax: +7 (499) 135 5085. E-mail: bubnov@ineos.ac.ru

N-*tert*-Butoxycarbonyl-7- and *N*-*tert*-butoxycarbonyl-8-bromo-10-azabicyclo[4.3.1]deca-3,7-dienes are convenient substrates for further modification using replacement of the Br atom by a cyano group or a Li atom. Treatment of lithium derivatives with dimethylformamide and *N*-methoxy-*N*-methylacetamide gave the corresponding α,β -unsaturated aldehydes (67–84%) and ketones (~70%). Ketone **4b** is a direct precursor of a homolog of the alkaloid ferruginine.

Key words: nitrogen heterocycles, bromopyridines, *cis*- and *trans*-2,6-diallyl-3-piperideines, *trans/cis* isomerization, metathesis, vinyl bromides, acylation, ferruginine.

Bridged azabicyclic compounds exhibit a broad spectrum of biological activity.¹ Recently, we have developed an efficient method of designing various bridged azabicycles, including 7- and 8-bromo-10-azabicyclo[4.3.1]deca-3,7-dienes (**1a,b**), starting from substituted pyridines, isoquinolines, and pyrrole. This method involves a combination of diallylboration and intramolecular metathesis.² The conditions of the synthesis allows such an important functional group as vinylic bromide to be retained in heterocycles (Scheme 1).

Scheme 1



R¹ = H, R² = Br (**1a**), R¹ = Br, R² = H (**1b**)

* Dedicated to Academician G. A. Abakumov on the occasion of his 70th birthday.

In the present work, we described the synthesis of formyl-, acetyl-, and cyano-10-azabicyclo[4.3.1]deca-3,7-dienes from earlier prepared bromides **1a,b**. We demonstrated the possibility of constructing the framework of a homolog of the alkaloid ferruginine. Ferruginine itself is highly neuroactive and is being investigated for treatment of Alzheimer's disease.^{1c}


Results and Discussion

The presence of the vinylic Br atom in compounds **1a,b** allows their modification. One way involves replacement of the Br atom by a cyano group. A reaction of compound **1a** with CuCN (3 equiv.)³ in *N*-methylpyrrolidone (NMP) gave nitrile **2a** in 42% yield (Scheme 2).

Alternatively, the Br atom can be replaced by lithium. The action of Bu^tLi in Et₂O–THF on compounds **1a,b** at –78 °C followed by treatment of the resulting lithium derivatives with dimethylformamide and hydrolysis gave the corresponding aldehydes **3a** and **3b** in 67 and 84% yields, respectively (Schemes 2, 3). The high yield of compound **3b** can be associated with more efficient lithiation, probably because of the directing effect of the Boc-protecting group. Such an effect is highly probable since coordination of the Boc group with the Li atom can produce a six-membered ring, while in the case of compound **1a**, this coordination is impossible.


Treatment of lithium derivative (**1b**-Li) with *N*-methoxy-*N*-methylacetamide (Weinreb's amide)⁴ afforded dienone **4b** (70%). The use of other reagents (dimethylacetamide, ethyl acetate, Ac₂O, or acetonitrile) led only to trace amounts of ketone **4b**. In the series of the

Scheme 2



Reagents and conditions: *i.* NMP, 150 °C, 4 h. *ii.* Bu^tLi (2 equiv.), Et₂O/THF, –78 °C.

Scheme 3



Reagents and conditions: *i.* Bu^tLi (2 equiv.), Et₂O/THF, –78 °C.

tropane bicycles, a transformation of compounds of the type **4b** into ferruginine homologs (**4c**) is a well-developed process⁵ involving selective reduction of the inactivated C=C bond in the presence of RhCl(Ph₃P)₃, removal of the protecting group, and reductive N-methylation.

In conclusion, we discovered convenient ways of modifying bridged bromoazabicycles and proposed a strategy of the synthesis of a homolog of the alkaloid ferruginine.

Experimental

Reactions were carried out under purified argon. All solvents were purified and dried according to standard procedures. NMR spectra were recorded on Bruker Avance-300, Bruker Avance-400, and Bruker Avance-600 spectrometers. Mass spectra were recorded on a Finnigan Polaris Q Ion Trap instrument. Column chromatography was carried out on silica gel (60–230 mesh, Merck). Compounds **1a,b** were prepared as described earlier.^{2a}

N-tert-Butoxycarbonyl-8-cyano-10-azabicyclo[4.3.1]deca-3,7-diene (2a). Cuprous cyanide (0.27 g, 3.0 mmol) was added to a solution of bromide **1a** (0.31 g, 1.0 mmol) in *N*-methylpyrrolidone (5 mL). The reaction mixture was heated at 150 °C for 4 h, cooled to 20 °C, and diluted with water (25 mL) and brine (10 mL). The product was extracted with *n*-hexane—Et₂O (2 : 1) (3×10 mL). The combined extracts were dried with K₂CO₃, the solvent was removed under reduced pressure, and the residue was chromatographed in *n*-hexane—EtOAc (10 : 1). The yield of compound **2a** was 0.11 g (42%), oil. Found (%): C, 69.30; H, 7.79; N, 10.67. C₁₅H₂₀N₂O₂. Calculated (%): C, 69.20; H, 7.74; N, 10.76. The signals in the NMR spectra are broadened and doubled because of hindered rotation of the amide group. ¹H NMR (400 MHz, C₆D₆), δ: 5.34 (br.s, 1 H); 5.15 (br.m, 1 H); 4.91 (br.m, 1 H); 4.95, 4.14 (both br.s, 1 H total); 4.23, 3.88 (both m, 1 H total); 2.26 (br.d, 0.53 H, *J* = 16.9 Hz); 2.08–1.98 (two overlapping br.d, 1 H total); 1.87 (br.d, 0.5 H, *J* = 15.5 Hz); 1.76, 1.73 (both dt, 1 H total, *J* = 2.6 Hz, *J* = 8.0 Hz); 1.48–1.42 (m, 0.82 H); 1.38–1.32 (m, 0.84 H); 1.26–1.07 (m, 1.4 H); 1.13 (br.s, 9 H). ¹³C NMR (100 MHz, C₆D₆), δ: 153.85; 142.94, 141.81; 128.76, 128.31; 127.68, 127.13; 118.16; 110.91, 110.23; 79.56; 48.93, 47.87; 44.71, 43.16; 35.30, 34.76; 33.14, 32.59; 30.10 (2 C); 28.13 (3 CH₃). MS (EI, 70 eV), *m/z*: 261 [MH]⁺ (7); 205 (20); 204 (35); 187 (37); 159 (45); 149 (30); 119 (20); 105 (100); 80 (65); 57 (23).

N-tert-Butoxycarbonyl-8-formyl-10-azabicyclo[4.3.1]deca-3,7-diene (3a). A 1.7 *M* solution of Bu^tLi in *n*-pentane (2.5 mL, 4.2 mmol) was added dropwise at –78 °C to a solution of bromide **1a** (0.62 g, 2.0 mmol) in Et₂O—THF (1 : 1, 12 mL). The mixture was stirred for 2.5 h. Then a solution of dimethylformamide (0.44 mL, 6.0 mmol) in Et₂O (1 mL) was added dropwise. The mixture was stirred at the same temperature for 10 min and treated with 3 *M* HCl (2 mL, 6.0 mmol) at 20 °C. The organic layer was washed with brine, dried with K₂CO₃, and concentrated under reduced pressure. The residue was chromatographed in *n*-hexane—EtOAc (8 : 1). The yield of compound **3a** was 0.35 g (67%), m.p. 41–42 °C. Found (%): C, 68.47; H, 8.09; N, 5.16. C₁₅H₂₁N₂O₃. Calculated (%): C, 68.42; H, 8.04; N, 5.32. The signals in the NMR spectrum are doubled because of hindered rotation of the amide group. ¹H NMR (300 MHz, CDCl₃), δ: 9.52, 9.50 (both s, 1 H total); 6.60, 6.54 (both d, 1 H total, *J* = 3.2 Hz); 5.76–5.72, 5.51–5.48 (both m, 2 H total); 5.16, 5.00 (both br.s, 1 H total); 4.79–4.73, 4.64–4.59 (both m, 1 H total); 2.87–2.73 (m, 1 H); 2.61–2.15 (m, 5 H); 1.54, 1.53 (both s, 9 H total).

***N*-tert-Butoxycarbonyl-7-formyl-10-azabicyclo[4.3.1]deca-3,7-diene (3b)** was obtained analogously from bromide **1b**. The yield was 0.39 g (84%), oil. Found (%): C, 68.40; H, 8.07; N, 5.26. $C_{15}H_{21}NO_3$. Calculated (%): C, 68.42; H, 8.04; N, 5.32. The signals in the NMR spectra are broadened and doubled because of hindered rotation of the amide group. 1H NMR (300 MHz, $CDCl_3$), δ : 9.34 (s, 1 H); 6.95, 6.90 (both s, 1 H total); 5.74 (br.m, 1 H); 5.52 (br.m, 1 H); 5.24, 5.07 (both s, 1 H total); 4.71, 4.59 (both m, 1 H total); 2.81, 2.75 (both d, 1 H total, $J = 8.2$ Hz); 2.56–2.49 (m, 3 H); 2.32–2.23 (m, 2 H); 1.52 (br.s, 9 H). ^{13}C NMR (75 MHz, $CDCl_3$), δ : 191.37, 191.00; 154.47, 154.23; 150.10, 148.92; 140.56, 140.19; 130.30, 129.48; 128.48, 127.73; 80.23, 79.99; (46.66, 45.59, 44.19) (2 C); 36.19, 35.73; 33.16, 32.78; 30.78 (2 C); 28.50 (3 CH_3).

***N*-tert-Butoxycarbonyl-7-acetyl-10-azabicyclo[4.3.1]deca-3,7-diene (4b)**. A 1.7 M solution of Bu^tLi in *n*-pentane (2.5 mL, 4.2 mmol) was added dropwise at $-78^\circ C$ to a solution of bromide **1b** (0.62 g, 2.0 mmol) in Et_2O –THF (1 : 1, 12 mL). The mixture was stirred for 2.5 h. Then a solution of *N*-methoxy-*N*-methylacetamide (0.41 g, 4.0 mmol) in Et_2O (1 mL) was added dropwise. The mixture was successively stirred at $-70^\circ C$ (1 h), $-50^\circ C$ (1 h), and $20^\circ C$ (10 h) and treated with 3 M HCl (2 mL, 6.0 mmol). The organic layer was washed with brine, dried with K_2CO_3 , and concentrated under reduced pressure. The residue was chromatographed in *n*-hexane– $EtOAc$ (5 : 1), $R_f = 0.2$. The yield of compound **4b** was 0.39 g (70%), an oil. Found (%): C, 69.31; H, 8.40; N, 4.97. $C_{16}H_{23}NO_3$. Calculated (%): C, 69.29; H, 8.36; N, 5.05. The signals in the NMR spectra are broadened and doubled because of hindered rotation of the amide group. 1H NMR (400 MHz, $CDCl_3$), δ : 6.95, 6.90 (both s, 1 H total); 5.66 (br.m, 1 H); 5.41 (br.m, 1 H); 5.18, 5.03 (both s, 1 H total); 4.55, 4.41 (both m, 1 H total); 2.64, 2.58 (both dd, 1 H total, $J = 2.1$ Hz, $J = 8.1$ Hz); 2.55–2.36 (m, 3 H); 2.20, 2.18 (both s, 3 H total); 2.14–2.06 (m, 2 H); 1.41–1.40 (both s, 9 H total). ^{13}C NMR (100 MHz, $CDCl_3$), δ : 196.37, 195.97; 154.55, 154.25; 140.49, 139.53; 138.76, 138.40; 130.64, 129.88; 128.39, 127.70; 79.86, 79.63; 46.92, 45.89; 44.91, 43.74; 35.98, 35.52; 33.56, 33.18; 30.30 (2 C); 28.46 (3 CH_3); 25.19, 25.10. MS (EI, 70 eV), m/z : 277 $[M]^+$ (1.0); 221 (7); 204 (12); 177 (23); 162 (15); 134 (10); 122 (82); 80 (100); 57 (5); 41 (15).

This work was financially supported by the Russian Foundation for Basic Research (Project No. 05-03-33268), the Council on Grants of the President of the Russian Federation (Program for State Support of Lead-

ing Scientific Schools and Young Russian Scientists, Project NSh-2878.2006.3), and the Presidium of the Russian Academy of Sciences (Program "Development of Methods for the Synthesis of Chemical Compounds and Creation of Novel Materials. Development of the Methodology of Organic Synthesis and Creation of Compounds with Valuable Applied Properties").

References

- (a) G. A. Cordell, *Introduction to Alkaloids, A Biogenetic Approach*, Wiley-Interscience, New York, 1981; (b) M. Lounasmaa and T. Tamminen, in *The Alkaloids, The Tropane Alkaloids*, Academic Press, New York, 1993, Vol. **44**, 1–114; (c) K. L. Swanson and E. X. Albuquerque, *Handb. Exp. Pharmacol.*, 1992, **102**, 620.
- (a) N. Yu. Kuznetsov, V. N. Khrustalev, I. A. Godovikov, and Yu. N. Bubnov, *Eur. J. Org. Chem.*, 2006, 113; (b) N. Yu. Kuznetsov, K. A. Lyssenko, A. S. Peregudov, and Yu. N. Bubnov, *Izv. Akad. Nauk, Ser. Khim.*, 2007, 1510 [*Russ. Chem. Bull., Int. Ed.*, 2007, **56**, 1569].
- L. A. Hammad and P. G. Wenthold, *J. Am. Chem. Soc.*, 2003, **125**, 10796.
- (a) S. Nahm and S. M. Weinreb, *Tetrahedron Lett.*, 1981, **22**, 3815; (b) V. K. Khlestkin and D. G. Mazhukin, *Curr. Org. Chem.*, 2003, **7**, 967; (c) J. Singh, N. Satyamurthi, and I. S. Aidhen, *J. Prakt. Chem.*, 2000, **342**, 340; (d) M. Mentzel and H. M. R. Hoffmann, *J. Prakt. Chem.*, 1997, **339**, 517; (e) M. P. Sibi, *Org. Prep. Proc. Int.*, 1993, **25**, 15.
- (a) E. Saikali and W. B. Young, *J. Org. Chem.*, 1991, **56**, 5696; (b) H. M. L. Davies, E. Saikali, N. J. S. Hubby, V. J. Gilliatt, and J. J. Matasi, *J. Med. Chem.*, 1994, **37**, 1262; (c) H. M. L. Davies, J. J. Matasi, L. M. Hodges, N. J. S. Hubby, C. Thornley, N. Kong, and J. H. Houser, *J. Org. Chem.*, 1997, **62**, 1095; (d) V. K. Aggarwal, C. J. Astle, and M. Rogers-Evans, *Org. Lett.*, 2004, **6**, 1469; (e) T. Katoh, K. Kakiya, T. Nakai, S. Nakamura, K. Nishide, and M. Node, *Tetrahedron: Asymmetry*, 2002, **13**, 2351; (f) D. M. Mans and W. H. Pearson, *Org. Lett.*, 2004, **6**, 3305.

Received January 23, 2007;
in revised form February 21, 2007